Clinical trial for peanut allergy treatment commences
Using selected fragments of peanut proteins, Australian biotechnology company Aravax has developed a product that switches off allergic reactions. The product is designed to be safer, more rapid and more convenient than other approaches currently under development.
The company has just commenced clinical trials of the potentially life-changing product and anticipates that simple, monthly injections will be sufficient to achieve clinical benefit.
Around 2% of Australians suffer from peanut allergy, and currently there is no therapy to reduce the severity of allergic reactions that can occur following accidental consumption. Despite patients attempting to follow a peanut-free diet, every year about 40% of peanut-allergic individuals will suffer a serious adverse event from inadvertent exposure.
Traditionally, allergy specialists have treated patients using repeated doses of the allergy-causing substance. Similar approaches are being developed to treat peanut allergy, but the use of preparations containing whole peanut protein carries a high risk of severe reactions and requires daily dosing for lengthy periods. Aravax’s product is different because it does not contain the parts of peanut protein that cause severe allergic reactions, and its once-a-month dosing regimen is a far simpler solution than remembering to take medication every day.
In the first ever trial of its product known as PVX108, Aravax will evaluate the safety and tolerability of single and repeated administration across a wide range of doses to determine an appropriate dosing regimen. This double-blinded and placebo-controlled trial commenced dosing on 10 May, with the first group of subjects safely receiving the lowest dose of PVX108. The trial is being conducted at CMAX Clinical Research in Adelaide and at Nucleus Network in Melbourne.
Aravax’s technology is underpinned by over a decade of research led by Professor Robyn O’Hehir and her team at Alfred Health and Monash University, which has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust and the National Health and Medical Research Council. In 2015, Aravax secured over $4.85 million from the Medical Research Commercialisation Fund (MRCF) to develop the technology through to initial clinical trials.
“We want to help people around the world who suffer from peanut allergy to live stress-free lives without constantly fearing a major health event from accidental consumption. Our technology aims to alleviate that stress by reprogramming the immune system to tolerate peanuts. By creating a safe, convenient and fast solution to a very serious problem, we believe our product will have a global health impact by transforming the lives of patients and their carers,” said Pascal Hickey, CEO of Aravax.
Peanut allergy sufferers interested in participating in the trials are invited to refer to the Aravax website for further information.
A new nationwide study of young baby boomers contradicts the popular belief that fast-food...
Parents choosing foods for their children are significantly more likely to purchase 'health...
In a study conducted by researchers at the University of Adelaide and published in...